Showing 11-20 of 61 results for "".
GLP-1RAs and the Dermatologist
https://practicaldermatology.com/issues/novemberdecember-2025/glp-1ras-and-the-dermatologist/48885/We are only beginning to understand the implications of GLP-1s for skin and systemic health. These medications are here to stay, and dermatology must be part of the conversation.How Outsourcing Services Can Benefit Your Practice: Considerations for a Busy Practice
https://practicaldermatology.com/topics/practice-management/how-outsourcing-services-can-benefit-your-practice-considerations-for-a-busy-practice/20339/Credentialing can be a tedious, time-consuming process. Outsourcing to someone with expertise can help.New in My Practice: Rx/New Products
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/new-in-my-practice-rxnew-products/23522/Take 5: Innovations in Aesthetic Treatments
https://practicaldermatology.com/columns/take-5/take-5-innovations-in-aesthetic-treatments/21746/Five new or emerging products may expand skin rejuvenation options.5 Missed Revenue Opportunities in Selling Skincare in Your Practice
https://practicaldermatology.com/topics/practice-management/5-missed-revenue-opportunities-in-selling-skincare-in-your-practice/20334/Most practices leave revenue on the table by making common skincare sales mistakes.Stop Making Sense…Make Up Words Instead
https://practicaldermatology.com/topics/practice-management/stop-making-sensemake-up-words-instead/23827/Practical Dermatology® Magazine Recognizes Top Content
https://practicaldermatology.com/topics/practice-management/practical-dermatology-magazine-recognizes-top-content/20563/Here's the most popular content from Practical Dermatology® brands online.DermWireTV: Incyte's Opzelura, BMS Patient Week, Science of Skincare Summit
https://practicaldermatology.com/topics/psoriasis/dermwiretv-incytes-opzelura-bms-patient-week-science-of-skincare-summit/20003/Incyte’s Opzelura is the first topical JAK inhibitor approved in the US. Lawrence Eichenfield, MD weighs in on the cream formulation of ruxolitinib for treatment of mild-to-moderate atopic dermatitis in non-immunocompromised patients 12 years of age and older. Bristol Myers Squibb's seventh Global PWhat’s New in Topical Acne Treatment?
https://practicaldermatology.com/topics/acne-rosacea/whats-new-in-topical-acne-treatment/23277/Emerging Technology: A Look at Nano-Pulse Stimulation
https://practicaldermatology.com/topics/skin-cancer-photoprotection/emerging-technology-a-look-at-nano-pulse-stimulation/23336/NPS is emerging as a novel technology platform for general and aesthetic dermatology.